West Family Investments Inc. Acquires 696 Shares of Cencora, Inc. (NYSE:COR)

West Family Investments Inc. increased its position in Cencora, Inc. (NYSE:COR) by 25.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,380 shares of the company’s stock after purchasing an additional 696 shares during the period. West Family Investments Inc.’s holdings in Cencora were worth $761,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. New Millennium Group LLC bought a new position in shares of Cencora during the second quarter valued at $26,000. TFO Wealth Partners LLC purchased a new stake in shares of Cencora during the first quarter worth about $30,000. MFA Wealth Advisors LLC purchased a new position in Cencora during the 2nd quarter valued at approximately $30,000. Concord Wealth Partners purchased a new position in shares of Cencora in the 3rd quarter worth approximately $30,000. Finally, LRI Investments LLC bought a new stake in shares of Cencora during the 1st quarter worth approximately $31,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Trading Down 1.1 %

COR stock opened at $240.19 on Tuesday. Cencora, Inc. has a 52 week low of $194.56 and a 52 week high of $251.56. The company has a market cap of $47.33 billion, a price-to-earnings ratio of 32.34, a PEG ratio of 1.60 and a beta of 0.44. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The business has a fifty day simple moving average of $232.62 and a 200-day simple moving average of $231.04.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.92%. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on COR shares. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Bank of America reissued a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.